Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 18, Issue 12, pp. 2194-2206
PubMed
Published By
Print ISSN
Online ISSN
History
- Received December 16, 2018
- Revision received June 12, 2019
- Accepted August 6, 2019
- Published first August 13, 2019.
Article Versions
- Previous version (August 13, 2019 - 07:19).
- You are viewing the most recent version of this article.
Copyright & Usage
©2019 American Association for Cancer Research.
Author Information
- Andreas Weiss1,
- Flavia Adler1,
- Alexandra Buhles1,
- Christelle Stamm1,
- Robin A. Fairhurst2,
- Michael Kiffe3,
- Dario Sterker1,
- Mario Centeleghe1,
- Markus Wartmann1,
- Jacqueline Kinyamu-Akunda4,
- Heiko S. Schadt5,
- Philippe Couttet5,
- Armin Wolf5,
- Youzhen Wang6,
- Patrizia Barzaghi-Rinaudo1,
- Masato Murakami1,
- Audrey Kauffmann1,
- Thomas Knoepfel2,
- Nicole Buschmann2,
- Catherine Leblanc2,
- Robert Mah2,
- Pascal Furet2,
- Jutta Blank7,
- Francesco Hofmann1,
- William R. Sellers6, and
- Diana Graus Porta1,*
- 1Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel, Switzerland.
- 2Novartis Institutes for Biomedical Research, Global Discovery Chemistry, Basel, Switzerland.
- 3Novartis Institutes for Biomedical Research, PK Sciences, Basel, Switzerland.
- 4Novartis Institutes for Biomedical Research, Preclinical Safety, East Hanover New Jersey.
- 5Novartis Institutes for Biomedical Research, Preclinical Safety, Basel, Switzerland.
- 6Novartis Institutes for Biomedical Research, Oncology Disease Area, Cambridge, Massachusetts.
- 7Novartis Institutes for Biomedical Research, Chemical Biology and Therapeutics, Basel, Switzerland.
- ↵*Corresponding Author:
Diana Graus Porta, Novartis Institutes for BioMedical Research, Klybeckstrasse 141, Basel 4002, Switzerland. Phone: +41-61-6965093; Fax: +41-61-6966242; E-mail: diana.graus_porta{at}novartis.com
December 2019
Volume 18, Issue 12
Volume 18, Issue 12
FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
Jump to section
Advertisement